Initiated Outperform X

CTIC CTI BioPharma

SVB Leerink

$13

Initiated Buy X

CTIC CTI BioPharma

Jefferies

$13

Initiated Outperform X

CTIC CTI BioPharma

Cowen

$10

Initiated Buy X

CTIC CTI BioPharma

Stifel

$5.50

Initiated Buy X

CTIC CTI BioPharma

Lake Street

$4

Initiated Buy X

CTIC CTI BioPharma

Needham

$10

Initiated Mkt Outperform X

CTIC CTI BioPharma

JMP Securities

$8

CTIC  CTI BioPharma Corp.

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.